In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals in Depth: January 2011

Executive Summary

Eli Lilly and Boehringer Ingelheim signed a risk-sharing deal worth over $2 billion to co-develop several diabetes candidates. To gain access to viral cancer vaccines, Amgen paid $425 million up front for BioVex, which could get another $575 million in regulatory and sales earn-outs. Three fundraises (from Symphogen, Nektar, and Pharmasset) that brought in over $100 million each contributed significantly to the $1.1 billion in biopharma financing. For the first time in six months, no device company completed a public offering in January - money invested in this industry totaled only $188 million, a 52% decrease from December's $391 million.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

IV003607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel